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Clinical trialsA number of smallmoleculeswith the ability to extend the lifespan ofmultiple organisms have recently been dis-
covered. Resveratrol, amongst themost prominent of these, has gainedwidespread attention due to its ability to
extend the lifespan of yeast, worms, andﬂies, and its ability to protect against age-related diseases such as cancer,
Alzheimer's, and diabetes inmammals. In this review, we discuss the origins andmolecular targets of resveratrol
and provide an overview of its effects on the lifespan of simplemodel organisms andmammals.We also examine
the unique ability of resveratrol to extend the healthy years, or healthspan, ofmammals and its potential to coun-
teract the symptoms of age-related disease. Finally, we explore the many scientiﬁc, medical, and economic chal-
lenges faced when translating these ﬁndings to the clinic, and examine potential approaches for realizing the
possibility of human lifespan extension. This article is part of a Special Issue entitled: Resveratrol: Challenges
in translating pre-clinical ﬁndings to improved patient outcomes.
Crown Copyright © 2015 Published by Elsevier B.V. All rights reserved.1. In pursuit of an elixir of life
The quest to discover of an elixir capable of prolonging lifespan and
retarding aging has been on-going since ancient times. However, only
recently has modern molecular genetics succeeded in identifying key
genes and pathways involved in the aging process, bringing us closer
to realizing this goal. Experimental manipulations of insulin signaling
[1], AMPK signaling [2], TOR signaling [3], and the Sir2 gene [4] have
all been demonstrated to modulate lifespan in diverse organisms. Fur-
thermore, a number of dietary and pharmacological interventions
have recently been described that can extend lifespan and prevent
age-related diseases, bolstering hope that it may one day be possible
to extend human lifespan. For example, caloric restriction (CR), a die-
tary regimen involving a reduction in caloric intake, extends the lifespan
of yeast [5], worms [6], ﬂies [7], and rodents [8]. Moreover, while one
study found that CR had no effect on the lifespan ofmonkeys [9], a series
of more recent studies reported that CR can reduce age-related and
all-cause mortality in rhesus monkeys [10–12]. As an alternative to CR,
dietary supplementation with a small molecule such as rapamycin
[13], metformin [14], spermidine [15], or resveratrol [16] has also
been shown to extend the lifespan of multiple model organisms. Of
these compounds, resveratrol has been the most widely studied mole-
cule in the context of aging-research, not only due its apparent lack of
toxicity [17], but also due to its remarkable ability to treat and counter-
act a number of age-related diseases in mammals, including heartatrol: Challenges in translating
).
r B.V. All rights reserved.disease, cancer, Alzheimer's disease, and diabetes [17,18]. Here, we
provide an overview of lifespan extension by resveratrol in numerous
organisms, and discuss its ability to extend the healthspan of mammals.
Furthermore, we provide perspective on the many controversies,
challenges, and future promises of translating theseﬁndings to the clinic.
2. Discovery of resveratrol and its link to the sirtuin longevity
pathway
Resveratrol (3,5,4′-trihydroxystilbene) was ﬁrst described in 1939
in ethanol extracts of the white hellebore Veratrum grandiﬂorum, and
initially characterized as a phytoalexin [17,19]. Subsequently, resvera-
trolwas shown to be present in grapevines and inwine [17]. Resveratrol
exists in two isomeric conﬁgurations, trans-(E) and cis-(Z), which may
undergo isomerization upon exposure to ultraviolet radiation [20]. The
4-hydroxystilbene skeleton in resveratrol has been shown to act as an
antioxidant pharmacophore, displaying a potent ability to scavenge
free radicals [21,22].
Following its discovery, multiple studies have demonstrated health-
enhancing properties of resveratrol both in vitro and in vivo in a number
of model organisms [18]. Early studies focused on the antioxidant
capacity of resveratrol, demonstrating that resveratrol can inhibit for-
mation of copper-catalyzed LDL oxidation [23], and inhibit peroxidation
of membrane lipids in liver microsomes [24]. Later, it was discovered
that resveratrol could restrict the release of inﬂammatory mediators
contributing to cardiovascular disease [25]. This ﬁnding was proposed
to resolve the ‘French paradox’, that certain European populations con-
suming large amounts of wine have low rates of cardiovascular disease
despite their high-fat diets [18]. Furthermore, a landmark study in 1997
demonstrated that topical application of resveratrol is extremely
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extended by reports showing that resveratrol can prevent both the for-
mation and growth of multiple types of cancers [17]. Shortly thereafter,
a neuroprotective role for resveratrol was identiﬁed [27]. Many of these
beneﬁcial effects were shown to be mediated by cyclooxygenases,
NF-κB, and AP-1, key mediators of inﬂammation and carcinogenesis
[28,29]. While few studies have reported negative health effects of
resveratrol, two early studies implicated dietary administration of
resveratrol in increased atherosclerosis [30] and DNA damage [31].
A small molecule screen for activators of the mammalian sirtuin
SIRT1 led to the discovery that resveratrol can extend the lifespan of
budding yeast [32]. Sirtuins comprise an evolutionary conserved family
of NAD+-dependent (class III) histone and protein deacetylases with a
wide variety of biological functions [33,34]. The founding member of
this protein class, Sir2, was initially characterized in yeast as a factor
involved in transcriptional silencing at mating loci and telomeres [35].
Later, it was discovered that overexpression of Sir2 in yeast results in
an ~30% lifespan extension [4,36], and that overexpression of Sir2
homologs in Caenorhabditis elegans [37] and Drosophila melanogaster
[38] also increases lifespan. In mice, whole-body over-expression of
SIRT6 extends the lifespan of males [39], and brain-speciﬁc over-
expression of SIRT1 extends lifespan as well [40], while whole body
overexpression of SIRT1 does not appear to affect longevity [41].
Because Sir2 consumes NAD+, a metabolic intermediate linked to
nutrient levels [33,34], it was proposed that the Sir2 enzyme could
underlie lifespan extension by caloric restriction [42]. While initial
reports [5,42] showing Sir2-dependent lifespan extension by CR in
yeast were challenged [43], a critical role for sirtuins in yeast CR wasFig. 1. Physiological functions andmolecular targets of SIRT1. SIRT1 deacetylates awide array of
and muscle Arnt-like protein-1, eNOS: Endothelial NOS synthase, FOXO1: Forkhead box O1, FO
mTOR: Mammalian target of rapamycin, ROCK1: Rho-associated protein kinase 1, NF-κB: Nucle
1-alpha, UCP2: Uncoupling protein 2.later re-afﬁrmed [44]. In addition, studies in mammals have shown
that the Sir2 homologs SIRT1 and SIRT3 are implicated in several of
the health beneﬁts attributed to CR [45–48].
SIRT1, which has been proposed to be a central target of resveratrol
in mammals [32,49], has been the most well-characterized of the
seven mammalian sirtuins (SIRT1–7) [50]. SIRT1 regulates numerous
cellular processes such as DNA repair, fat differentiation, glucose output,
insulin sensitivity, fatty acid oxidation, and neurogenesis, through
deacetylation of a number of key histone and protein targets including
H3-K9, H4-K16, H1-K26, nuclear factor NF-κB, PPAR-gamma co-
activator 1α (PGC1α), forkhead box transcription factors (FOXOs), and
numerous others (Fig. 1) [18,34,50,51]. Importantly, overexpression of
SIRT1 has been demonstrated to guard against Alzheimer's disease [52,
53], cancer [41,54], type II diabetes [55], and cardiovascular disease
[18,56]. Resveratrol and similar polyphenols (e.g. ﬂavones, stilbenes,
and chalcones) were initially reported to activate SIRT1 in vitro through
a direct allosteric mechanism involving a lowering of the peptide sub-
strate KM [32]. Consistent with this hypothesis, lifespan extension in
yeast by resveratrol was shown to be Sir2-dependent [32]. Whether or
not SIRT1 is directly activated by resveratrol has been the subject of a
contentious debate [18]. A series of studies challenged the early
in vitro data, suggesting that resveratrol could be binding to an artiﬁcial
ﬂuorophore on the peptide used in the initial high-throughput screen-
ing assay, rather than allosterically modulating SIRT1 [57,58].
Furthermore, it was suggested that the in vivo effects of resveratrol on
SIRT1 could simply be due to off-target effects on other enzymes such
as phosphodiesterase (PDE) [59]. However, several recent reports have
validated the initial model by identifying an allosteric site on SIRT1 toimportant non-histone targets, resulting in effects onmany cellular processes. BMAL: Brain
XOs: Forkhead box proteins, FOXP3: Forkhead box P3, HIF-1: Hypoxia-inducible factor 1,
ar factor kappa-B, PGC1α: Peroxisome proliferator-activated receptor gamma co-activator
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peptide substrates [60,61], supporting the hypothesis that SIRT1 is
indeed a primary target of resveratrol action in vivo.
3. Lifespan extension by resveratrol in small model organisms
In addition to extending the lifespan of yeast up to 70% in a Sir2-
dependent manner [32], the ability of resveratrol to promote longevity
is highly conserved in other organisms (Table 1). Treatment of ﬂies in
early adulthood with 100 μM resveratrol was shown to extend mean
lifespan [16]. The same dose of resveratrol was demonstrated to in-
crease mean worm lifespan also, without any changes in fecundity
[16]. In both cases, lifespan extension was originally shown to be Sir2-
dependent [16]. However, these ﬁndings were challenged by a report
claiming that resveratrol supplementation only marginally increases
lifespan of C. elegans and D. melanogaster, and that this small effect is
preserved in Sir2-mutant strains [62]. Indeed, it has been questioned if
the Sir2 gene itself even plays any role in determining longevity in
worms or ﬂies [63]. Recent work has supported the original ﬁndings
[64] and sheds light on some of the subtleties of the debate. In ﬂies, it
appears as though the effect of resveratrol on lifespan depends on
both gender and dietary nutrient composition [65].
Resveratrol dosed at 130 μM also extends the mean lifespan of the
common honey bee by up to 33%, in addition to extending maximum
lifespan [66]. While a Sir2-dependence for this phenomenon has not
been tested, bees fed resveratrol ingest fewer quantities of food under
ad libitum feeding conditions, suggesting a caloric restriction-likemech-
anism [66]. In the short-lived ﬁsh species Nothobranchius furzeri and
Nothobranchius guentheri, resveratrol extends both median and maxi-
mum lifespan [67–69] and delays age-dependent decay of locomotor
activity [67]. In contrast, resveratrol administration does not affect the
lifespan of the crustacean Daphnia pulex [70].
Physiological and environmental stressors may promote the early
onset of a number of age-associated diseases. In certain instances, short-
ened lifespan resulting from exposure to stressors such as radiation orTable 1
Lifespan extension by resveratrol in various species. The ability of resveratrol to extend org
diet, N.O.: not observed.
Organism Species Mean lifes
Saccharomyces cerevisiae 70%
C. elegans
C. elegans
10–14%
9–18%
D. melanogaster
D. melanogaster
D. melanogaster
(females only)
29%
10–17%
10–15%
Apis mellifera 33–38%
N. fuzeri
N. guentheri
33–56% (m
19%
Mus musculus (SD)
M. musculus (HFD)
N.O.
31%a
a Resveratrol supplementation reduced the risk of death from a high-calorie diet by 31%.oxidative stress may be counteracted by resveratrol supplementation
[71]. For example, resveratrol treatment was found to increase resis-
tance to oxidative stress and ameliorate damage caused by oxidative
stress in C. elegans [72]. Similarly, resveratrol exhibits radioprotective
effects and alleviates radiation-induced damage in worms [73], and in
fruit ﬂies [74]. Finally, resveratrol counteracts the effects of amyloid tox-
icity in worms, thereby attenuating symptoms of induced-
neurodegeneration [75]. Thus, in addition to increasing the maximum
lifespan of several species, resveratrol can attenuate the lifespan short-
ening effect caused by a number of diseases and physiological stressors.
4. Effects of resveratrol on the lifespan of healthy mammals
While there is now substantial evidence suggesting that the lifespan-
extending effects of sirtuins are conserved inmice [39], no study has yet
reported lifespan extension resulting from resveratrol treatment in
healthymammals. To date, three studies examining the effects of resver-
atrol supplementation on wild-type healthy mice have been performed
[76–78]. The ﬁrst of these studies employed mice fed a standard diet ad
libitum with a resveratrol supplementation protocol beginning at
12 months of age (mid-life) [76]. Two subsequent studies, which uti-
lized supplementation protocols beginning at 9 [77], and 4 months of
age [78], conﬁrmed that resveratrol treatment does not extend the
lifespan of healthy, genetically heterogeneous mice. Rats dosed with
red wine or equivalent pharmacological doses of resveratrol do not
live longer, but do display improved vascular aging phenotypes [79].
No large-scale study has attempted tomeasure the effects of resveratrol
on human lifespan.
5. Lifespan extension by resveratrol in metabolically compromised
mammals
While no study has demonstrated lifespan extension by resveratrol
in healthy, wild-type mammals, studies have shown that resveratrol
supplementation can increase the lifespan of metabolicallyanismal lifespan is conserved from yeast to mammals. HFD: high-fat diet, SD: standard
pan extension Maximum lifespan extension References
[32]
[16]
[156]
20–22% [16]
[157]
[65]
[66]
Ed.) 27–59%
28%
[67]
[68]
N.O. [76,78,80]
[80]
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caused by environmental insult [81]. A landmark paper by Baur et al.
[80] showed that resveratrol treatment shifts the physiology of mice
on a high-calorie diet to that of mice on a standard diet, reducing the
risk of death due to high-calorie feeding by ~31%. In addition, resvera-
trol increased insulin sensitivity, reduced IGF-1 levels, activated
AMPK/PGC-1α signaling, improved mitochondrial parameters, and im-
proved liver and motor function of mice fed a high-calorie diet in this
study [80]. Subsequent studies have conﬁrmed that resveratrol protects
against hepatic steatosis by decreasing lipogenesis and inﬂammation in
these mice [82]. Moreover, resveratrol has been shown to stimulate mi-
tochondrial biogenesis, and attenuate oxidative stress in regulatory T
cells when fed to mice on a high-fat diet [83]. At the molecular level,
the effects of resveratrol on metabolically compromised mice appear
to involve both AMPK and SIRT1 [49]. Studies using conditional SIRT1-
knockout mice have shown that resveratrol activates AMPK in a highly
dose-dependent manner; a low dose (~24 mg/kg) stimulates AMPK in
a SIRT1-dependent manner via LKB1, while a high dose of resveratrol
(~240 mg/kg) displays SIRT1-independent AMPK activation [49].
The ability of resveratrol to suppress the damaging effects of a high-
fat/high-calorie diet does not appear to be conﬁned to mice [84]. Two
recent studies have illustrated the beneﬁts of resveratrol supplementa-
tion on the health of rhesus monkeys fed a high-fat/high-sucrose diet
[84,85]. In theﬁrst study, resveratrol improved adipose insulin signaling
and reduced inﬂammation in adipose tissue caused by the diet [84]. A
second study revealed that resveratrol prevents high-fat/high-sucrose
diet-induced arterial wall inﬂammation and stiffening [85]. Findings
from these studies could be very relevant to humans, as the modern
‘Western diet’ mimics a high-fat/high-sugar diet in many ways [80].
Currently, there exists no consensus regarding the effects of resver-
atrol onmetabolically compromised humans. Some reports have shown
that resveratrol supplementation improves metabolic parameters in
humans [86], while other studies show no such beneﬁts [87]. For exam-
ple, one recent study examining the effects of 30-day resveratrol sup-
plementation (150 mg/day resVida) on energy metabolism and
metabolic proﬁle showed that resveratrol caused a calorie restriction-
like phenotype [86]. Patients in this study displayed a decrease in
intrahepatic lipid content, circulating glucose, triglycerides, inﬂamma-
torymarkers, and systolic blood pressure [86]. Furthermore, resveratrol
supplementation appears to improve bone mineral density in obese
men [88], and improve insulin sensitivity in humans via modulation of
the Akt pathway [89]. In contrast, a separate study found that resvera-
trol had no effect on blood pressure, energy expenditure, lipid metabo-
lism or inﬂammatory markers in obese men [87]. Also, while one study
reported an improvement in inﬂammatory biomarkers in patients with
non-alcoholic fatty liver disease following 500 mg treatment with res-
veratrol for 12 weeks [90], a separate study showed no such beneﬁt
[91]. Lastly, thirty-day supplementation with resveratrol was reported
to suppress postprandial glucagon in obese human patients, but had
no effect on postprandial incretin hormone responses [92].
6. Lifespan extension by resveratrol in the context of othermamma-
lian diseases
Speciﬁc individuals within a given population may be more or less
susceptible to a particular set of diseases due to their genetic predispo-
sition. In small-scalemammalian lifespan studies, it is difﬁcult to resolve
the effects of a compound such as resveratrol on relatively rare genetic
disorders affecting only a small subset of the population. Nonetheless,
directed lifespan studies using resveratrol in several disease models
have uncovered very interesting results [93–95]. Resveratrol treatment
has been documented to attenuate symptoms and prolong the lifespan
of mammals suffering from several genetic diseases of the brain [93,94].
Two recent reports showed that resveratrol supplementation improves
motor-neuron function and extends the lifespan of the SOD1(G93A)
mousemodel of amyotrophic lateral sclerosis (ALS) [93,94]. Furthermore,dietary resveratrol supplementation was shown to prevent Alzheimer's
disease markers and increase the lifespan of the senescence-accelerated
mouse (SAMP8), which over-produces amyloid precursor protein (APP)
in the brain, leading to oxidative damage [95]. In a mouse knockout
model of HtrA2 (Huntington's disease), resveratrol extended lifespan
and delayed worsening of the motor phenotype via regulation of the
Bax pathway [96]. Resveratrol administration also improves survival in
a rat model of hypertension [97]. Importantly, however, disease morbid-
ity has also been increased by resveratrol in certain cases: at concentra-
tions ranging from 50–100 mg/kg/day, resveratrol worsened survival of
mice with prostate cancer [98].
Lethality due to exposure to environmental toxins, pathogens, and ra-
diation may be prevented by resveratrol supplementation in several in-
stances. First, resveratrol has been shown to attenuate catecholamine-
induced mortality in obese rats, partly by reducing oxidative stress via
the Nrf2 pathway [99]. Likewise, resveratrol increases the lifespan of
LPS-treated mice [100]. Resveratrol also appears to be effective in
protecting against insults from bacterial pathogens [101]. In a mouse
model of sepsis-induced acute kidney injury, resveratrol restored renal
microcirculation and prolonged survival [101]. Finally, resveratrol alters
tumor load and increases the lifespan of mice subjected to ionizing radi-
ation [81]. Thus, while the effects of resveratrol in general population
studies ofmammalian lifespanhave beenminimal, its potential to extend
lifespan in the context of a number of diseases has been remarkable.7. Healthspan increase and disease prevention in mammals by
resveratrol
Aging in mammals is marked by a complex set of physiological de-
clines that do not always correlate with maximum lifespan. Thus, the
concept of ‘healthspan’, the number of healthy or disease-free years of
an organism's lifespan, may be a comparably important measure of
the aging process. Several studies have demonstrated that resveratrol
can prevent/revert a number of physiological changes associated with
aging in mammals, and promote optimal health [17]. Pearson et al.
reported that resveratrol supplementation induces gene expression
patterns in several tissues that mimic those observed during dietary
restriction or every-other-day feeding in mice [76]. Furthermore, res-
veratrol treatedmice show a reduction in a number of physiological de-
clines linked to aging, including decreased inﬂammation, decreased
apoptosis in the vascular endothelium, increased aortic elasticity, im-
proved motor coordination, reduced cataract formation, and decreased
osteoporosis, relative to non-treated counterparts [76]. An independent
study conﬁrmed the striking resemblance in the transcriptional proﬁle
of mice on a caloric restriction regimen, and mice given resveratrol
[102]. Also, it was shown that resveratrol has the ability tomimic the ef-
fects of caloric restriction on insulin-mediated glucose uptake inmuscle
[102]. These effects appear to be conserved in higher organisms as well,
as both caloric restriction and resveratrol supplementation result in im-
proved insulin sensitivity markers in the primate Microcebus murinus
[103]. In humans, resveratrol supplementation improves glycemic con-
trol [104] and modulates inﬂammatory-related microRNAs in patients
with type 2 diabetesmellitus [105], but has no effect on insulin sensitiv-
ity in obese men [87].
A large amount of data shows that resveratrol may delay or prevent
the onset of commondiseases of aging including cancer, Alzheimer's dis-
ease, and diabetes [18]. Resveratrol was shown to substantially reduce
both overall tumor development and especially thymic lymphomas
and sarcomas in mice subjected to gamma irradiation [81]. The latter
effects were SIRT1-dependent [81]. Resveratrol also slows the growth
of a number of tumors including colon and prostate [54,158], while its
effects on tumors of the breast remainmore controversial [18]. A clinical
study using the resveratrol formulation SRT501 reported a 39% increase
in apoptosis markers in malignant hepatic tissue following treatment
[106].
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to prevent accumulation of beta-amyloid peptide [107], and reduce
plaque formation [108], two processes which likely contribute to the
onset of Alzheimer's disease [108]. Finally, roles in protecting against
both type I and type II diabetes have been demonstrated for resveratrol
[17,109]. For example, resveratrol is able to prevent chemically-induced
diabetes in mice by inhibiting apoptosis of pancreatic β-cells [110], and
it prevents β-cell de-differentiation in monkeys subjected to a high-fat/
high-sugar diet [111].
Resveratrol mediates its protection against inﬂammatory disorders
and cardiovascular disease through several mechanisms [17]. In part
due to its inhibition of the cyclooxygenase enzymes COX-1 and COX-2,
resveratrol is able to inhibit inﬂammation caused by infectious agents
such as Listeria monocytogenes, which typically infects patients who
are either immunocompromised or elderly [112]. Debilitating muscle
and joint diseases associatedwith old agemay be averted by resveratrol
supplementation; a study in rabbits demonstrated protection against
experimentally-induced arthritis [113]. The cardioprotective effects of
resveratrol have been extensively documented previously [114], and
may arise from the antioxidant andmetal chelating properties of resver-
atrol, which prevent oxidation of low-density lipoprotein (LDL) parti-
cles [17]. Few studies have yet to examine the effects of resveratrol on
disease prevention in healthy humans. One recent study reported that
resveratrol supplementation in humans (70 mg/day) does not improve
metabolic function, or have any effect on plasma lipids or inﬂammatory
makers throughout a 12-week trial period [115]. The controversial
effects of resveratrol in healthy humans have been previously summa-
rized [109]. However, further longer-term and larger-scale studies will
need to be conducted to determine if the many disease-preventing
actions of resveratrol observed in mice are conserved in humans.
8. Lifespan and healthspan extension by resveratrol in humans:
clinical challenges and promises
Resveratrol has demonstrated great promise in the laboratory as
both a lifespan and healthspan extending molecule [17]. However,
translating ﬁndings with resveratrol from model systems to the clinicAnoxidant
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Aryl hydrocarbon receptor, AMPK: AMP-activated protein kinase, COX: Cyclooxygenase, CYPs:
Phosphodiesterase 4, PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator 1
Kinase.will require overcoming several challenges and obstacles. First, there
are numerous logistical and economic hurdles that would need to be
addressed if a large-scale study of the effects of resveratrol on human
lifespan were to be performed. Logistically, it would be very difﬁcult
to carry on such a long-term clinical study, due to both patient and
researcher compliance. Furthermore, the cost of such a study would
be enormous. A general study on the disease preventing beneﬁts of res-
veratrol in humans would face similar challenges. Therefore, it is likely
that any general beneﬁcial effects of resveratrol on human health will
ﬁrst be reported as ancillary observations in disease-speciﬁc clinical
trials, or from non-governmentally regulated studies. Indeed, it has
been estimated that 66% of people in the US who consume multiple
dietary supplements consume resveratrol [109,116].
Resveratrol regulates awide array of proteinswithin the cell, resulting
in complex pharmacodynamics that could complicate its use in the clinic.
Whether SIRT1 is a direct target of resveratrol has been the subject of in-
tense debate [57,58,117,118]. Moreover, resveratrol targets a number of
other enzymes, kinases, and receptors (Fig. 2) [17,50,118,125,127]. For
example, resveratrol inhibits the activity of various cytochrome P450s
(CYPs), enzymes that are involved in phase I drug metabolism [17,119,
120], and also decreases their transcription via inhibition of the aryl hy-
drocarbon receptor (AHR) [17,121]. Quinone reductase 2 (QR2), also in-
volved in drug metabolism, is potently inhibited by resveratrol [122]. In
addition to these, resveratrol inhibits the cyclooxygenase enzymes
COX-1 and COX-2, resulting in potent anti-inﬂammatory effects [123]. Fi-
nally, resveratrol inhibits a number of important kinases including PKD,
which plays an important role in cell proliferation, and S6 kinase, which
acts to mediate cell autophagy [124,125]. The striking ability of resvera-
trol to simultaneously regulate a number of key enzymes, all in amanner
which appears to enhance health and longevity, has led to the
‘xenohormesis hypothesis’ [126]. This hypothesis states that an organism
can sense chemical cues from other species about harsh environmental
conditions or a low food supply, and can respond by initiating a physio-
logical defensemechanism to increase its odds of survival; the production
of resveratrol is thought to be one such cue [127]. Thus, the chemical
structure of resveratrol may have evolved to inﬂuence multiple stress-
defense targets such as SIRT1, COX-2, and QR2 [17,127]. While theT1
GC-1α
itochondrial 
Biogenesis
tension
Metabolism 
& Autophagy
AMPK
S6K
CYPs
Lower Toxicity and 
Carcinogenesis
rocesses that mediate its ability to extend lifespan and prevent age-related diseases. AhR:
Cytochrome P450 family, FOXO3: Forkhead box O3, NF-κB: Nuclear factor kappa-B, PDE4:
-alpha, PKCδ: Protein kinase C-δ, ROS: Reactive oxygen species, S6K: Ribosomal protein S6
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range of diseases, they also complicate its pharmacological analysis,mak-
ing it difﬁcult to predict how resveratrol would be tolerated by different
sub-groups of patients in a large-scale clinical setting.
Studies on the bioavailability, pharmacokinetics, and tissue distribu-
tion of resveratrol suggest that it may not be an ideal clinical drug can-
didate [18,159]. Resveratrol from natural sources appears to be poorly
absorbed by humans [128]. Humans receiving 25 mg/70 kg of body
weight of resveratrol formulated in a wine-based matrix for 4 weeks
failed to achieve plasma concentrations within the therapeutic window
of 5–100 μM [128]. Similarly, Gresele et al. [129] determined that after
15 days of consumption of 300mL of wine (white or red), the total plas-
ma resveratrol concentration, including metabolites, was only slightly
increased above background. Moreover, studies with puriﬁed resvera-
trol supplements have demonstrated poor systemic absorption [109].
For example, dietary supplementation with 5 g of trans-resveratrol in
humans yielded a 24-hour mean plasma concentration of ~52 ug/L
over the course of a day, with maximum plasma concentration (Cmax)
being observed 1.5 h after administration [109]. Multiple studies have
now conﬁrmed that resveratrol has a short half-life in vivo and reaches
a low Cmax due to its rapid metabolism and conversion into byproducts
such as trans-resveratrol-3-sulfate, trans-resveratrol-disulfates, and
trans-resveratrol-glucuronides [17,130,131]. Indeed, peak levels of two
resveratrol metabolites, sulfate-conjugates and glucuronic acid-
conjugates, have been reported to have blood levels 3- and 8-fold
higher, respectively, than the unmodiﬁed molecule [132]. Interestingly,
a recent report has demonstrated that resveratrol sulfate-conjugates
can be taken up by several tissues, and that subsequent processing can
regenerate free unmodiﬁed resveratrol inside cells [133]. Human gut
microbiota may also limit bioavailability of resveratrol through conver-
sion into metabolites such as 3,4′-dihydroxy-trans-stilbene and 3,4′-
dihydroxybibenzyl [134]. Other factors affecting the bioavailability of
unmodiﬁed resveratrol include the time of intake (high bioavailability
after morning intake), prior food intake, and fat content in food [135–
137]. Lastly, resveratrol and its metabolic derivatives seem to partition
in vivo in a tissue speciﬁcmanner, adding further complexity to its over-
all pharmacology [138].
One of the remarkable pharmacological properties of resveratrol is
its apparent lack of toxicity in animals [17]. In rats, doses of resveratrol3,5-Dihydroxy-4'-acetoxy- -
slbene
3,5-Dihydroxy-4'-methyl- -
slbene SRT1
SRT1
A B
Fig. 3. Resveratrol analogues and synthetic SIRT1 activating compounds. A) Chemically modiﬁe
C), benzimidazole and urea-based STACs (numbered according to a previously described convup to 300 mg per kg of body weight show no detrimental effects [139].
Consistent with this ﬁnding, preclinical and phase I clinical trials have
revealed that resveratrol is well tolerated in humans and that it does
not induce any major toxic complications [132,140,141]. Speculation
as to potential adverse effects of resveratrol center around its ability to
act as a phytoestrogen, and thereby potentially stimulate the growth
of breast cancer cells [142], and its ability to delay wound healing
[143]. Resveratrol also inhibits topoisomerase II [144], which could po-
tentially result in DNA damage and carcinogenesis. Moreover, several
reports have suggested that resveratrol should not be taken by pregnant
women since the fetus has diminished detoxiﬁcation systems and may
be more susceptible to these negative effects [145]. Overall, while pre-
clinical and small-scale clinical studies have demonstrated a wide-
array of health beneﬁts stemming from resveratrol supplementation,
further pharmacological optimization is necessary in order tomake res-
veratrol more suitable for larger-scale clinical trials.
9. Alternatives to resveratrol that may be more appropriate for
clinical use
Two parallel approaches are on-going to fully exploit resveratrol's
clinical potential: the design of new resveratrol formulations and ana-
logues with improved pharmacokinetics and bioavailability, and the
identiﬁcation of more potent synthetic SIRT1 activators. A proprietary
formulation of micronized resveratrol, SRT501, was shown to achieve
blood levels 5–8 times higher than resveratrol alone, concentrations
which approach levels that have been shown in animal models to
have numerous health-promoting effects [18,141,146]. In addition, a
number of resveratrol derivatives with hydrophobic substituents (e.g.
methyl, ethyl) at the 4′ position of the stilbene backbone display higher
lifespan extension in yeast than the parent compound, and are more
stable (Fig. 3A) [147].
While it is unlikely that all of resveratrol's health beneﬁts rely solely
on activation of SIRT1, several screens have successfully identiﬁed novel
SIRT1 activators that mimic many of its effects on healthspan and
lifespan [55,148]. Most notable are three classes of synthetic SIRT1 acti-
vators, or STACs, which have been developed by Sirtris Pharmaceuticals
(structures are shown in Fig. 3B and C). First generation STACs based on
an imidazothiazole scaffold, such as SRT1460, SRT1720, and SRT2183,460
720
STAC5
STAC9
C
d derivatives of resveratrol, B) synthetic STACs based on the imidazothiazole scaffold, and
ention [60]).
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to low micromolar potency in vitro [55]. Like resveratrol, the ability of
these compounds to activate SIRT1 has been questioned [117], and sub-
sequently re-afﬁrmed [60]. In addition to displaying beneﬁts in a num-
ber of human disease models [149,150], SRT1720 extends both the
lifespan and healthspan of mice fed a high-fat diet [151]. SRT1720 was
also recently reported to extend the lifespan of mice fed a standard
diet [152]. Similarly, SRT2104 has been shown to extend both mean
andmaximum lifespan ofmice on a standard diet, concomitantwith im-
provements in motor coordination, bonemineral density, insulin sensi-
tivity, mitochondrial efﬁciency, and decreased inﬂammation [153]. This
particular compound has also been the subject of extensive clinical trials
in humans, where it displayed high bioavailability, lack of toxicity, and
the ability to improve the serum lipid proﬁle of patients [154,155].
Third generation STACs including benzimidazoles and urea-based scaf-
folds display even higher maximal efﬁcacy and potency than second
generation STACs [60], and may constitute a viable pharmaceutical
alternative to resveratrol.
10. Concluding remarks
Given the ever growing list of molecules proven to extend the
lifespan and health of mammals, it is likely that a molecule capable of
extending human life has already been identiﬁed, or will be in the
near future. In the case of resveratrol, there are currently 93 on-going
or recently completed clinical trials (www.clinicaltrials.gov) in different
disease models and clinical settings that will likely produce data
answering critical questions regarding its effects on human health.
However, governmental regulatory agencies currently do not consider
aging a disease due its widespread occurrence, minimizing the possibil-
ity of testing resveratrol or similar molecules in clinical trials for aging.
Thus, from a scientiﬁc and medical perspective, the major challenges
moving forward will be determining how to identify molecules with
the ability to extend human life, and how to implement strategies for
testing them safely in the population. Additionally, many of the ethical
and philosophical questions surrounding human lifespan extension
will need to be examined in-depth. Although a tremendous amount of
work still lies ahead, there is no doubt that the discovery of a singlemol-
ecule capable of preventing and treating multiple age-related diseases
in humans will revolutionize modern-day medicine.
Transparency Document
The Transparency document associated with this article can be
found in the online version.
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